Skip to content
BHP

Peptides studied for irritable bowel syndrome research

Last reviewed:

IBS research increasingly focuses on gut-barrier integrity, low-grade inflammation, and microbial signalling — three domains in which research peptides have established pre-clinical activity.

Larazotide is the only research peptide on this page to have entered Phase II human trials, with published data demonstrating measurable reductions in intestinal permeability — a key mechanistic target in IBS research.

— Notable finding

Condition background

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder estimated to affect 10–15% of the UK population, characterised by abdominal pain associated with altered bowel habit in the absence of structural pathology detectable by standard investigation. Subtypes are classified by predominant stool pattern: IBS-C (constipation-predominant), IBS-D (diarrhoea-predominant), IBS-M (mixed), and IBS-U (unclassified). Pathophysiology is heterogeneous and incompletely understood but involves altered gut-brain axis signalling, visceral hypersensitivity (lowered pain thresholds in response to gut distension), intestinal permeability changes ('leaky gut'), low-grade mucosal immune activation, and dysbiosis. Post-infectious IBS — developing after gastroenteritis — provides a model in which the sequence of events linking mucosal injury to chronic sensorimotor dysfunction can be studied. Psychological co-morbidity (anxiety, depression) is common and bidirectionally linked to gut symptom severity through the gut-brain axis.

Current treatment landscape

UK IBS management is guided by NICE Clinical Guideline CG61, which emphasises dietary and lifestyle modification (increased fibre, reduced FODMAPs, regular meals) as primary interventions. Antispasmodics (mebeverine, hyoscine) are used for abdominal pain; laxatives for IBS-C; loperamide for IBS-D. Low-dose tricyclic antidepressants are recommended as second-line pain modulators, with SSRIs as an alternative. Psychological therapies (cognitive behavioural therapy, gut-directed hypnotherapy) are recommended for patients with refractory symptoms. Rifaximin, a non-absorbable antibiotic, is used off-label by some gastroenterologists for IBS-D with suspected small-intestinal bacterial overgrowth. The heterogeneous pathophysiology makes treatment response unpredictable, and a significant proportion of patients report persistent symptoms despite multimodal care.

Why peptides are studied here

Research peptide interest in IBS centres on three mechanistic domains. Gut-barrier restoration: [BPC-157](/peptides/bpc-157) has been shown to maintain tight-junction protein expression (claudin-4, occludin) in NSAID-damaged rodent intestinal epithelium and to restore mucosal integrity after ischaemia-reperfusion injury, making it relevant to the barrier dysfunction implicated in IBS-D and post-infectious IBS. Mucosal immune modulation: [KPV](/peptides/kpv) (a tripeptide fragment of alpha-melanocyte-stimulating hormone) suppresses NF-κB-driven mucosal inflammation through MC1R and intracellular pathways, reducing pro-inflammatory cytokines such as IL-8 and TNF-α that contribute to low-grade mucosal activation in IBS. Paracellular permeability: [Larazotide](/peptides/larazotide) (AT-1001) is a synthetic octapeptide specifically designed to inhibit zonulin-mediated tight-junction opening. Pre-clinical and Phase I/II human data have demonstrated larazotide's ability to reduce intestinal permeability and associated mucosal cytokine release, with the most extensive evidence base in coeliac disease but with mechanistic relevance to IBS-associated barrier dysfunction.

Relevant research peptides

Notable study findings

  • BPC-157

    In a rodent model of NSAID-induced intestinal injury, BPC-157 preserved expression of the tight-junction proteins claudin-4 and occludin, reduced bacterial translocation, and restored mesenteric microvascular flow, suggesting a role in maintaining barrier function relevant to IBS pathophysiology.

  • KPV

    KPV suppressed NF-κB activation and reduced IL-8 and TNF-α secretion in stimulated intestinal epithelial cell cultures, with effects attributable in part to direct intracellular delivery of the tripeptide — a finding relevant to low-grade mucosal inflammation in IBS.

  • Larazotide

    Phase II data (Kelly CP et al., Gastroenterology, 2013) in coeliac disease demonstrated that larazotide 0.5 mg three times daily significantly reduced intestinal permeability and decreased abdominal symptoms compared with placebo — mechanistic evidence applicable to IBS research involving barrier dysfunction.

Relevant research stacks

UK regulatory notes

BPC-157, KPV, and larazotide are not licensed by the MHRA for IBS or any other human indication in the UK. Larazotide has undergone Phase II human trials in coeliac disease but has not received regulatory approval from the FDA, MHRA, or EMA. BPC-157 is listed on the WADA Prohibited List under S0. KPV and larazotide are not currently WADA-listed. All content is for laboratory research reference only.

Frequently asked questions

What is the gut barrier and why does it matter in IBS research?
The intestinal epithelial barrier is a single-cell layer separating the gut lumen — containing food antigens, microbes, and their metabolites — from the lamina propria and systemic circulation. Tight junctions between epithelial cells regulate paracellular permeability. When tight-junction integrity is impaired, bacterial products and luminal antigens access the subepithelial immune system, potentially driving the low-grade mucosal inflammation and visceral hypersensitivity observed in a subset of IBS patients.
How does larazotide work differently from BPC-157 in gut research models?
Larazotide is a tight-junction regulator — it specifically inhibits the zonulin pathway that drives paracellular permeability, acting at the epithelial cell surface. BPC-157 has broader effects: it restores mucosal blood flow via the NO system, promotes epithelial migration, reduces pro-inflammatory cytokines, and maintains tight-junction protein expression through multiple parallel mechanisms. They target overlapping but distinct aspects of barrier function.
Is KPV derived from a naturally occurring protein?
Yes. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH), itself a cleavage product of pro-opiomelanocortin (POMC). α-MSH has known anti-inflammatory properties mediated through melanocortin receptors, and KPV retains these properties while being small enough to cross intestinal epithelium and act intracellularly in some models.
Does BPC-157 have any clinical evidence in IBS specifically?
No human trials of BPC-157 in IBS have been published in indexed journals as of the date of this review. All mechanistic data relevant to IBS derives from rodent models of NSAID-induced enteropathy, colitis, and ischaemia-reperfusion, which share pathological features with IBS but are not equivalent to the clinical syndrome.
What dietary approaches does NICE recommend for IBS in the UK?
NICE CG61 recommends a regular meal pattern, adequate hydration, and fibre modification (soluble fibre preferred). A low-FODMAP diet (restricting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) is widely used in dietetic practice as a second-line intervention. This page focuses on research peptides and does not constitute dietary advice.
Are larazotide trials relevant to IBS or only coeliac disease?
Published Phase II larazotide trials have used coeliac disease as the primary model, partly because intestinal permeability endpoints are more standardised and measurable in that population. However, the mechanism — inhibition of tight-junction opening via zonulin pathway blockade — is directly relevant to IBS research, particularly the post-infectious and IBS-D subtypes in which barrier dysfunction has been documented.

Where to source research peptides for laboratory research

The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.

  • PeptideAuthority.co.uk

    UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.

  • PeptideBarn.co.uk

    Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.